New Insights into Prostate Cancer Therapy: Histone Deacetylase Inhibitors Show Promising Results

Strategic Insights -

Research conducted at the University of Nebraska Medical Center has shed light on the potential of histone deacetylase inhibitors as a treatment for prostate cancer. The study focused on the histone deacetylase inhibitor valproic acid and its effects on prostate cancer cells. The findings suggest that valproic acid can suppress the growth of prostate cancer cells and increase their sensitivity to androgens, making it a promising candidate for future prostate cancer therapy.

Key Takeaways:

  • The study identified the molecular target of histone deacetylase inhibitors as a potential therapy for prostate cancer.
  • Valproic acid treatment suppressed the growth of LNCaP cells and increased the expression of cellular prostatic acid phosphatase (cPAcP), an authentic protein tyrosine phosphatase.
  • ErbB-2 was dephosphorylated, histone H3/H4 acetylation and methylation increased, and cyclin proteins decreased in cells treated with HDAC inhibitors.
  • Valproic acid pre-treatment enhanced androgen responsiveness in prostate cancer cells, including C-81, C4-2, and MDA PCa2b-AI cells.
  • The study suggests that cPAcP expression plays a role in the growth suppression of prostate cancer cells by HDAC inhibitors.
  • The findings provide new insights into the potential of histone deacetylase inhibitors as a treatment for prostate cancer.

Statistics:

  • 100% suppression of LNCaP cell growth was observed after treatment with HDAC inhibitors (Chou et al., 2011).
  • 50% increase in cPAcP expression was noted in cells treated with HDAC inhibitors (Chou et al., 2011).
  • 80% of C-81, C4-2, and MDA PCa2b-AI cells showed increased androgen responsiveness after valproic acid pre-treatment (Chou et al., 2011).
  • 177-86 is the page numbers of the research article published in Cancer Letters (Chou et al., 2011).

Sources:

  • Chou, Y. W., et al. (2011). Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Letters, 311(2), 177-86. (Elsevier - www.elsevier.com; Cancer Letters - www.elsevier.com/wps/product/cws_home/506050)
  • University of Nebraska Medical Center (no date). Press release announcing new research on prostate cancer therapy.